Fragile X syndrome: Research & Drug Discovery Data

Drug discovery

drugs

With orphan designations

Overview

Fragile X syndrome (FXS) is a genetic disorder caused by a CGG trinucleotide repeat expansion (>200 repeats) in the FMR1 gene on the X chromosome, leading to reduced production of fragile X mental retardation protein (FMRP). This results in intellectual disability, developmental delays, autism spectrum features (33% of cases) [1][6], anxiety, ADHD, and characteristic physical traits (long face, large ears, macroorchidism) [1][6][16]. Males are typically more severely affected due to X-linked inheritance [12][17].

Population

Affects ~1:7,000 males and ~1:11,000 females [7][12][19]
Most common inherited cause of intellectual disability [7][16]
Carrier frequency: 1:150-300 females and 1:400-850 males [2][10]

Burden

Incremental annual healthcare costs: $33,409/person (Medicaid) [4][9]
35% require ER visits, 34% use home services, 25% need intensive therapies [4][9]
44% of caregivers report significant productivity loss [9][14]

Therapies

Multidisciplinary care: Speech-language, occupational, and physical therapies [3][16][18]
Pharmacotherapy: SSRIs (sertraline), stimulants (methylphenidate), and antipsychotics (aripiprazole) for anxiety, ADHD, and aggression [8][18]
Early intervention: Behavioral strategies and environmental modifications to enhance function [3][6][16]

Categories: rare developmental anomalies during embryogenesis, rare endocrine diseases, rare genetic diseases, rare neurological diseases, rare ophthalmic disorders

Research Papers

1,543 drug discovery papers about Fragile X syndrome, with 6 first-in-class and 30 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

2026-08-06 | FYN, a Novel Target of Fragile X Mental Retardation Protein, Potentially Underlies ERK1/2 Hyperactivation in Fragile X Syndrome.

Fragile X syndrome (FXS), the most common inherited form of intellectual disability and the leading monogenic cause of autism, results from the loss of the fragile X mental retardation protein (FMRP). Dysregulated translation of FMRP target mRNAs is believed to underlie the aberrant synaptic plasticity observed in FXS. Identification of these targets is critical for elucidating disease mechanisms and developing therapeutic strategies. We confirmed the interaction between FMRP and FYN mRNA by RNA immunoprecipitation in HEK293 and SH-SY5Y cells and assessed FYN translational regulation via polyribosome profiling in FXS and control lymphoblastoid cells. The role of FYN in ERK hyperactivation was examined in FXS lymphoblastoid cells, FMR1-knockdown SH-SY5Y cells, and dfmr1 mutant flies. Additionally, we tested whether reducing or inhibiting Src64B, a Drosophila Src family kinase with homology to human FYN, could rescue neural and behavioral defects in dfmr1 mutants. FMRP bound to FYN mRNA and suppressed its translation without affecting mRNA stability. Phosphorylated ERK1/2 levels were markedly elevated in FXS lymphoblastoid cells, and this hyperactivation was largely reversed by either the Src family kinase inhibitor PP2 or siRNA-mediated FYN knockdown, supporting an important role for FYN in ERK1/2 dysregulation. Similar changes were observed in FMR1-knockdown SH-SY5Y cells, with increased FYN expression and ERK1/2 phosphorylation, and PP2 treatment attenuated the abnormal ERK1/2 phosphorylation. Furthermore, genetic or pharmacological suppression of Src64B restored ERK signaling and rescued mushroom body defects and memory deficits in dfmr1 mutants. This study identifies FYN as a novel translational target of FMRP and suggests that its upregulation may contribute to hyperactivation of ERK1/2 signaling in FXS.

Open article ↗

2026-08-06 | Computational investigation for exploring botanical ingredients as potential negative allosteric modulators targeting metabotropic glutamate receptor 5.

Metabotropic glutamate receptors are class C G-protein-coupled receptors that respond to the neurotransmitter glutamate. In particular, metabotropic glutamate receptor 5 (mGluR5) has been a valuable drug target for the management of psychiatric and neurodegenerative disorders such as fragile X syndrome, autism, depression, anxiety, addiction, and movement disorders through negative allosteric modulators (NAMs). Despite the discovery of several NAMs, limited clinical efficacy was observed, thus preventing them from reaching the clinical stage. Natural products are indispensable, with a plethora of pharmacological actions. This study aimed to identify potential natural compounds as novel natural NAMs modulating mGluR5 using a comprehensive in silico approach. Utilizing receptor-based pharmacophore modelling, we virtually screened a natural library comprised of ~1.2 million compounds to study their molecular binding behavior against mGluR5. Furthermore, the best hits were evaluated using the end-point method (molecular mechanics Poisson-Boltzmann surface area), molecular dynamics (MD) simulations, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling. Based on the augmented computational modelling, we identified four promising natural hits-3'-HPS, gigantol, isorhapontigenin, and coclaurine that demonstrated higher affinities than the standard clinical candidate 2-methyl-6-phenylethynyl-pyridine (MPEP), and co-crystal 2-[2-(3-methoxyphenyl)ethynyl]-6-methyl-pyridine (M-MPEP). The top selected hits demonstrated optimal binding energies, molecular interactions, and favorable ADMET properties with a few toxicity liabilities, warranting further lead optimization and experimental validations. MD simulations validated their structural stability through RMSD, RMSF, and principal component analysis. Our findings provided compelling evidence for a structure-based drug design approach in developing potent small-molecule natural modulators for the treatment of neurodegenerative disorders.

Open article ↗

2026-08-05 | Advancing mental health and well-being of Nigerian children through public health screening for Fragile X disorders (CHAMP-FX): protocol of a prospective multicentre screening study with longitudinal follow-up.

There is an increasing burden of neurodevelopmental disorders worldwide, with scarce data in low and middle-income countries, including Nigeria. Little is known about Fragile X disorders (Fragile X syndrome and Fragile X premutation-associated conditions) in developing countries and there is no national data in Nigeria. Advancing Mental Health and Well-being of Nigerian Children Through Public Health Screening for Fragile X Disorders (CHAMP-FX) is a multicentre public health screening initiative designed to estimate the prevalence of Fragile X disorders among children with neurodevelopmental disorders in Nigeria through targeted screening, strengthen diagnostic capacity and provide pathways to targeted treatments. This is a prospective multicentre screening study with longitudinal follow-up recruiting children aged 1-18 years with intellectual disability, autism spectrum disorder, and/or global developmental delay from six tertiary hospitals across Nigeria's six geopolitical zones. Using purposive sampling, 102 participants (17 per zone) will be enrolled. Sociodemographic data and clinical evaluation will be obtained using KoboToolbox. Blood samples will be collected as dried spots on quick-response coded filter cards, stored with desiccant, and transported to the coordinating molecular laboratory. Genetic testing will be performed using a long-range amplification workflow followed by long-read sequencing to determine repeat sizes and classify results using internationally accepted thresholds. The primary outcome is the proportion of participants with Fragile X full mutation and/or premutation in the selected cohort. Secondary outcomes include the distribution of repeat sizes and associations with sociodemographic and clinical variables. Screen-positive participants will receive structured result disclosure, genetic counselling, and referral for appropriate supportive interventions, with targeted therapy using metformin offered to participants diagnosed with Fragile X syndrome. Findings will be disseminated through peer-reviewed publication, conferences and stakeholder engagement.

Open article ↗

2026-08-01 | The m6A-mediated epi-transcriptomic dysregulation drives synaptic dysfunction in fragile X syndrome.

Fragile X syndrome (FXS), the leading genetic cause of intellectual disability, arises from FMR1 gene silencing and the subsequent loss of the RNA-binding protein FMRP. N6-methyladenosine (m6A) is a prevalent mRNA modification essential for post-transcriptional regulation. FMRP binds and regulates the stability of m6A-containing transcripts. However, how FMRP deficiency impacts transcriptome-wide m6A modifications in FXS remains unknown. To address this, we generated cortical neurons from induced pluripotent stem cells (iPSCs) derived from healthy individuals and FXS patients. Electrophysiology recordings revealed synaptic and neuronal network defects in FXS iPSC-derived neurons. Transcriptome-wide analysis revealed striking m6A hypermethylation predominantly affecting synapse-associated transcripts. Mechanistically, we demonstrated that FMRP deficiency drives the aberrant translational upregulation of core m6A writers, a causal relationship definitively validated using CGG-corrected isogenic control lines. Targeted genetic knockdown of the m6A writer METTL3 successfully rescued synaptic phenotypes in FXS neurons, whereas its overexpression in control neurons phenocopied these synaptic defects, confirming the causal role of m6A dysregulation in FXS pathology. Notably, pharmacological intervention with the METTL3 inhibitor STM-2457 normalized methylation on synapse-associated transcripts and restored synaptic transmission in FXS neurons. Together, our findings uncover an FMRP-dependent epitranscriptomic mechanism contributing to FXS pathogenesis and suggest a promising avenue for m6A-targeted therapies.

Open article ↗

2026-07-19 | Astrocytic FMRP regulates the function of spinal parvalbumin-expressing neurons in Fragile X Syndrome

Abstract Tactile hypersensitivity is a common symptom of Fragile X Syndrome (FXS) characterized by over-responsiveness to innocuous touch or textures. Yet, the neural circuitry underlying this altered sensory processing remains incompletely understood. Previous studies have focused on cortical and peripheral neuron dysfunction. However, the spinal dorsal horn circuits, which make up the first central site of somatosensory integration, also comprises elements that could contribute to the hypersensitivity to innocuous stimuli, yet its involvement in this pathology has remained incompletely understood. Here, we show that spinal parvalbumin (PV)-expressing interneurons (PVNs), an inhibitory population that gates touch sensory input from activating nociceptive pathways, are dysfunctional in FXS. Using a mouse model of FXS (global Fmr1 knockout; gKO), we showed that dorsal horn PVNs exhibit impaired function characterized by reduced PV expression and inability to sustain tonic firing. To determine whether these deficits arise through cell-intrinsic mechanisms, we selectively deleted Fmr1 in PVNs. This deletion failed to reproduce the molecular and electrophysiological changes observed in the gKO mice. In contrast, astrocyte-specific deletion of Fmr1 recapitulated key features of the gKO mice, including decreased PV expression and firing. To understand the biophysical basis of this firing deficit, we simulated spinal PVNs using conductance-based Hodgkin-Huxley type modelling. Surprisingly, modifying intrinsic membrane conductances alone was insufficient to account for the experimental data. In fact, PVN firing required incorporation of an additional calcium-dependent extrinsic synaptic component consistent with the experimental finding that astrocytic, but not PVN-specific, loss of FMRP reproduced the PVN phenotype in gKO mice. Together, these findings show that these deficits in spinal PVNs arise primarily from loss of FMRP in astrocytes rather than in PVNs themselves. It reveals astrocyte-dependent dysfunction of dorsal horn inhibitory circuits as a previously uncharacterized consequence of FXS.

Open article ↗

2026-08-06 | FYN, a Novel Target of Fragile X Mental Retardation Protein, Potentially Underlies ERK1/2 Hyperactivation in Fragile X Syndrome.

Open article ↗

2026-08-06 | Computational investigation for exploring botanical ingredients as potential negative allosteric modulators targeting metabotropic glutamate receptor 5.

Open article ↗

2026-08-05 | Advancing mental health and well-being of Nigerian children through public health screening for Fragile X disorders (CHAMP-FX): protocol of a prospective multicentre screening study with longitudinal follow-up.

Open article ↗

2026-08-01 | The m6A-mediated epi-transcriptomic dysregulation drives synaptic dysfunction in fragile X syndrome.

Open article ↗

2026-07-19 | Astrocytic FMRP regulates the function of spinal parvalbumin-expressing neurons in Fragile X Syndrome

Open article ↗

Access all drug discovery papers and probability of success in trials forecasts:

Request access

Drug Discovery Landscape

53 orphan drug designations for Fragile X syndrome.

Drug	Therapy type	Regulator	Orphan designation	Approval	Sponsor
alkanoylamine derivative selective modulator of a Class A G protein coupled receptor	small molecules	FDA	2025-11-19	—	GEXVal Inc.
(R)-3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1methylethyl)benzamide	small molecules	EMA	2025-06-20	—	Somerville Development Partners B.V.
3-Chloro-4-fluorophenyl-[4-fluoro-4-[[(5-methylpyrimidin-2-ylmethyl) amino]methyl]piperidin-1-yl]methanone	small molecules	FDA	2025-02-28	—	Neurolixis, Inc.
small molecule modulator of large conductance, calcium-activated potassium (BK, KCa1.1) channels	small molecules	FDA	2024-11-19	—	Servier Pharmaceuticals LLC
3-chloro-4-fluorophenyl-(4-fluoro-4-(((5-methylpyrimidin-2-ylmethyl)amino)methyl)piperidin-1yl)methanone	small molecules	EMA	2024-11-11	—	Neurolixis
(R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide	small molecules	FDA	2024-05-14	—	Spinogenix, Inc.
Zatolmilast	small molecules	EMA	2024-03-21	—	Shionogi B.V.
5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione	small molecules	EMA	2023-03-20	—	Quality Regulatory Clinical Ireland Limited
blarcamesine	small molecules	FDA	2022-11-03	—	Anavex Life Sciences Corp.
Lisuride Maleate	small molecules	FDA	2022-10-24	—	NeuroVenti Inc.
replication-incompetent adeno-associated virus serotype 9 vector encoding the human fragile x mental retardation 1 gene	gene therapies	FDA	2022-06-16	—	Cincinnati Children's Hospital
Ibudilast	small molecules	FDA	2022-06-15	—	Healx Limited
4-(3-cyano-6-ethoxyquinolin-2-yl)-N- (2-fluorophenyl)-1,4-diazepane-1-carbothiomide	small molecules	FDA	2022-05-26	—	Neuronascent, Inc.
Ibudilast	small molecules	EMA	2022-05-16	—	Healx Technology Limited
Codergocrine mesilate, oxitriptan	small molecules	EMA	2022-03-16	—	Purposeful I.K.E.
Cannabidiol	small molecules	EMA	2022-02-24	—	QbD Flanders
Psilocybin	small molecules	FDA	2021-10-25	—	Nova Mentis Life Science Corp.
Psilocybine	small molecules	EMA	2021-10-15	—	Comac Medical Ltd.
2-[4-[3-(methylamino)-1-phenylpropoxy]phenyl]ethanol hydrochloride	small molecules	EMA	2021-05-20	—	Connecta Therapeutics S.L.
Sulindac	small molecules	FDA	2021-05-10	—	Healx Limited
Sulindac	small molecules	EMA	2020-12-09	—	Healx Technology Limited
Balipodect	small molecules	FDA	2019-06-13	—	Takeda Development Center Americas, Inc.
Balipodect	small molecules	EMA	2019-04-24	—	Takeda Pharma A/S
alpha tocopherol and ascorbic acid	small molecules	FDA	2019-03-28	—	GenCo Pharmaceuticals LLC
zatolmilast	small molecules	FDA	2018-03-26	—	Tetra Discovery Partners, Inc.
Cannabidivarin	small molecules	EMA	2018-02-22	—	Jazz Pharmaceuticals Ireland Limited
Gaboxadol	small molecules	FDA	2017-10-03	—	Healx Limited
5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione	small molecules	FDA	2017-06-12	—	Autifony Therapeutics Limited
Cannabidivarin	small molecules	FDA	2017-06-06	—	Jazz Pharmaceuticals Research UK Limited
N-[(1R)-1-phenylethyl]-6-{1H-pyrazolo[3,4-d]pyrimidin-4-yl}quinazolin-2-amine [SOL 784]	small molecules	EMA	2017-04-20	—	Propharma Group The Netherlands B.V.
Alpha-tocopherol and ascorbic acid	small molecules	EMA	2017-02-27	—	Advanced Medical Projects
ganaxolone	small molecules	FDA	2016-12-28	—	Marinus Pharmaceuticals
Pyridoxine and L-pyroglutamic acid	small molecules	EMA	2016-06-27	—	FGK Representative Service Ltd
cannabidiol	small molecules	FDA	2016-02-23	—	Harmony Biosciences Management, Inc.
(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one	small molecules	FDA	2015-12-09	—	Centre National de la Recherche Scientifique (CNRS)
Glycyl-L-2-methylprolyl-L-glutamic acid	small molecules	EMA	2015-07-28	—	Voisin Consulting Life Sciences
bryostatin 1	small molecules	FDA	2015-03-31	—	Synaptogenix, Inc.
Tideglusib	small molecules	EMA	2015-03-19	—	AMO Pharma Limited
(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one	small molecules	EMA	2014-10-15	—	Centre National de la Recherche Scientifique (CNRS)
Acamprosate calcium	small molecules	EMA	2014-10-15	—	Veristat Spain S.L.
metadoxine	small molecules	FDA	2013-12-16	—	Alcobra, Inc.
Trofinetide	small molecules	FDA	2013-10-23	—	ACADIA Pharmaceuticals Inc.
acamprosate	small molecules	FDA	2013-03-25	—	Confluence Pharmaceuticals, LLC
Mavoglurant [AFQ056]	small molecules	EMA	2012-10-10	—	Novartis Europharm Limited
acetyl-l-carnitine	small molecules	FDA	2012-07-24	—	Leadiant Biosciences, Inc.
basimglurant	small molecules	FDA	2012-03-09	—	Hoffmann-La Roche, Inc.
(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester	small molecules	FDA	2011-10-12	—	Stalicla SA
R-baclofen	small molecules	EMA	2011-04-15	—	Lakeside Regulatory Consulting Services Ltd
R-4-amino-3-(4-chlorophenyl)butanoic acid	small molecules	FDA	2008-11-28	—	Clinical Research Associates, LLC
3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethylnyl)-pyridin-2-yl]-benzonitrile dihydrochloride	small molecules	FDA	2008-07-28	—	Seaside Therapeutics
Valproate	small molecules	FDA	2008-05-05	—	Neuropharm Ltd,
Fenobam hydrochloride	small molecules	FDA	2006-11-20	—	Neuropharm, Ltd.
guanfacine	small molecules	FDA	1999-08-05	—	Watson Laboratories, Inc.

Fragile X syndrome

Fragile X syndrome

Fragile X syndrome

Overview

Population

Burden

Therapies

Categories: rare developmental anomalies during embryogenesis, rare endocrine diseases, rare genetic diseases, rare neurological diseases, rare ophthalmic disorders

Research Papers

2026-08-06 | FYN, a Novel Target of Fragile X Mental Retardation Protein, Potentially Underlies ERK1/2 Hyperactivation in Fragile X Syndrome.

2026-08-06 | Computational investigation for exploring botanical ingredients as potential negative allosteric modulators targeting metabotropic glutamate receptor 5.

2026-08-05 | Advancing mental health and well-being of Nigerian children through public health screening for Fragile X disorders (CHAMP-FX): protocol of a prospective multicentre screening study with longitudinal follow-up.

2026-08-01 | The m6A-mediated epi-transcriptomic dysregulation drives synaptic dysfunction in fragile X syndrome.

2026-07-19 | Astrocytic FMRP regulates the function of spinal parvalbumin-expressing neurons in Fragile X Syndrome

2026-08-06 | FYN, a Novel Target of Fragile X Mental Retardation Protein, Potentially Underlies ERK1/2 Hyperactivation in Fragile X Syndrome.

2026-08-06 | Computational investigation for exploring botanical ingredients as potential negative allosteric modulators targeting metabotropic glutamate receptor 5.

2026-08-05 | Advancing mental health and well-being of Nigerian children through public health screening for Fragile X disorders (CHAMP-FX): protocol of a prospective multicentre screening study with longitudinal follow-up.

2026-08-01 | The m6A-mediated epi-transcriptomic dysregulation drives synaptic dysfunction in fragile X syndrome.

2026-07-19 | Astrocytic FMRP regulates the function of spinal parvalbumin-expressing neurons in Fragile X Syndrome

Drug Discovery Landscape

Updated: Sep 6, 2026